pralsetinib + cisplatin

Pralsetinib + cisplatin is an **investigational anticancer combination regimen** that pairs pralsetinib, an oral selective RET tyrosine kinase inhibitor, with cisplatin, a platinum-based DNA-damaging chemotherapy. The biologic rationale is complementary: pralsetinib suppresses oncogenic signaling driven by altered RET, while cisplatin forms covalent platinum-DNA adducts and crosslinks that disrupt DNA replication and transcription and trigger tumor cell death. This combination is not a single co-formulated branded product; rather, it refers to concurrent use of the two agents within oncology treatment regimens or comparator settings involving platinum-based therapy. Pralsetinib was originally developed by Blueprint Medicines and later commercialized through partners including Roche and subsequently Rigel in certain contexts, whereas cisplatin is a long-established generic chemotherapy manufactured by multiple companies. The combination is most relevant to RET-driven solid tumors, especially non-small cell lung cancer treatment strategies in which cisplatin may be used as part of platinum-based regimens and pralsetinib provides targeted RET inhibition.

Other names

pralsetinib + cisplatin